Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Looking4Doubleson Mar 19, 2020 5:48pm

101 Views

Post# 30828333

RE:RE:RE:RE:1:100 RS = $1.50 🤑🤑🤑

LtGhost wrote: Then get the product to market first before doing anything else!

They should. They have a $15 Million dollar incentive to do just that & hence a 37.5% cut to Stero doesn't bother me if they help get us the private placement and line up major investment managers before any R/S. I am still hoping they make a jump to a bigger stock exchange at the same time, which could be a very positive move. (ie would give us more exposure and a lot more investors)

Bullboard Posts

Nevada gold stock scores multiple high-grade hits